

Sameer Bansilal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10611271/publications.pdf>

Version: 2024-02-01

49
papers

6,323
citations

279798

23
h-index

223800

46
g-index

50
all docs

50
docs citations

50
times ranked

8477
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	27.0	1,585
2	Strategies for Multivessel Revascularization in Patients with Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2375-2384.	27.0	1,573
3	¹⁸ Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible. <i>Journal of the American College of Cardiology</i> , 2007, 50, 892-896.	2.8	415
4	Atherosclerosis Inflammation Imaging with ¹⁸ F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations. <i>Journal of Nuclear Medicine</i> , 2008, 49, 871-878.	5.0	410
5	A Polypill Strategy to Improve Adherence. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2071-2082.	2.8	290
6	Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2009, 2, 107-115.	2.6	227
7	Global burden of CVD: focus on secondary prevention of cardiovascular disease. <i>International Journal of Cardiology</i> , 2015, 201, S1-S7.	1.7	219
8	Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 789-801.	2.8	208
9	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2732-2740.	2.8	179
10	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002475.	3.9	148
11	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	2.7	128
12	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	2.7	117
13	A Comprehensive Lifestyle Peer-Group-Based Intervention on Cardiovascular Risk Factors. <i>Journal of the American College of Cardiology</i> , 2016, 67, 476-485.	2.8	96
14	Role of Insulin Resistance and Hyperglycemia in the Development of Atherosclerosis. <i>American Journal of Cardiology</i> , 2007, 99, 6-14.	1.6	85
15	The SI! Program for Cardiovascular Health Promotion in Early Childhood. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1525-1534.	2.8	78
16	A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 613-621.	2.8	74
17	Family-Based Approaches to Cardiovascular Health Promotion. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1725-1737.	2.8	63
18	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	2.8	56

#	ARTICLE	IF	CITATIONS
19	Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>American Heart Journal</i> , 2011, 162, 214-221.e2.	2.7	50
20	Child Health Promotion in Underserved Communities. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2011-2021.	2.8	40
21	The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry. <i>American Heart Journal</i> , 2012, 164, 591-599.	2.7	34
22	Resistant in-stent restenosis in the drug eluting stent era. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 777-785.	1.7	26
23	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	2.7	25
24	Association Between a Social-Business Eating Pattern and Early Asymptomatic Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 805-814.	2.8	24
25	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	2.7	23
26	A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial. <i>American Heart Journal</i> , 2017, 184, 121-132.	2.7	22
27	Long-Term Cardiovascular Outcomes in Patients With Angina Pectoris Presenting With Bundle Branch Block. <i>American Journal of Cardiology</i> , 2011, 107, 1565-1570.	1.6	19
28	Rationale and Design of Family-Based Approach in a Minority Community Integrating Systems Biology for Promotion of Health (FAMILIA). <i>American Heart Journal</i> , 2017, 187, 170-181.	2.7	19
29	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.	1.7	13
30	Grenada Heart Project Community Health Action to Encourage healthy Behaviors (GHP-CHANGE): A randomized control peer group-based lifestyle intervention. <i>American Heart Journal</i> , 2020, 220, 20-28.	2.7	11
31	Cardiovascular Risk Surveillance to Develop a Nationwide Health Promotion Strategy: The Grenada Heart Project. <i>Global Heart</i> , 2012, 7, 87.	2.3	11
32	Different Lifestyle Interventions in Adults From Underserved Communities. <i>Journal of the American College of Cardiology</i> , 2020, 75, 42-56.	2.8	10
33	Dietary sodium intake among US adults with hypertension, 1999-2012. <i>Journal of Hypertension</i> , 2018, 36, 237-242.	0.5	8
34	Low intraoperative heart rate volatility is associated with early postoperative mortality in general surgical patients: a retrospective case-control study. <i>Journal of Clinical Monitoring and Computing</i> , 2016, 30, 911-918.	1.6	6
35	The North Karelia Project: The Spark That Ignited the Flame!. <i>Global Heart</i> , 2016, 11, 171.	2.3	5
36	Antithrombotic strategy variability in Atrial fibrillation and obstructive coronary disease revascularized with PCI: rationale and study design of the prospective observational multicenter AVIATOR 2 registry. <i>American Heart Journal</i> , 2015, 170, 1234-1242.	2.7	4

#	ARTICLE	IF	CITATIONS
37	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq1 1 0.784314 rgB4 /Overl	2.7	4
38	Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Coronary Artery Disease</i> , 2020, 31, 59-65.	0.7	4
39	The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations. <i>Journal of Atrial Fibrillation</i> , 2017, 9, 1547.	0.5	4
40	A Diabetes-Atrial Fibrillation Conundrum. <i>Journal of the American College of Cardiology</i> , 2016, 67, 248-250.	2.8	3
41	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.	1.7	2
42	Optimal treatment of the diabetic patient with multivessel disease. <i>Current Cardiology Reports</i> , 2008, 10, 272-284.	2.9	1
43	The role of reduced heart rate volatility in predicting disposition from the emergency department. <i>Emergency Medicine Journal</i> , 2017, 34, 289-293.	1.0	1
44	Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?. <i>Global Heart</i> , 2020, 11, 469.	2.3	1
45	Little Beacons of Change: Targeting Preschool Children to Drive a Culture of Health. <i>Global Heart</i> , 2020, 11, 467.	2.3	1
46	Diabetic multivessel disease: stenting vs. coronary artery bypass grafting. <i>Indian Heart Journal</i> , 2007, 59, B72-82.	0.5	1
47	Polymer-free stents in diabetic patients" not so sweet after all!. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 425-426.	1.7	0
48	Appropriate testing for stable ischaemic heart disease. <i>Nature Reviews Cardiology</i> , 2014, 11, 137-138.	13.7	0
49	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 599-600.	2.8	0